Advertisement
U.S. markets closed
Advertisement

Unicycive Therapeutics, Inc. (UNCY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.4900-0.0225 (-4.39%)
At close: 03:59PM EST
0.5145 +0.02 (+5.00%)
After hours: 07:46PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close0.5125
Open0.5074
Bid0.5087 x 1300
Ask0.5000 x 2200
Day's Range0.4900 - 0.5150
52 Week Range0.4000 - 2.8700
Volume104,410
Avg. Volume55,968
Market Cap17.03M
Beta (5Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-1.4700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for UNCY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Unicycive Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/23/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • GlobeNewswire

    Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

    LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023. Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)Presentation: Monday, December 4, 2023 at 3:30 pm ET Boca Rat

  • Simply Wall St.

    Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022)

    Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net loss: US$4.41m (loss...

  • GlobeNewswire

    Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

    Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a bus